Dr. Rossignol is a co-founder of the Company and has served as Chief Medical and Scientific Officer and Chairman of the Board of Directors since its inception. He studied chemistry at the University of Paris where he received a doctorate degree in synthetic organic/medicinal chemistry, and then studied medicine specializing in Clinical Parasitology & Tropical Medicine. He synthetized nitazoxanide, a first in class antimicrobial agent. Dr. Rossignol spent more than 30 years developing and registering drugs around the world at SmithKline & French Laboratories (now GlaxoSmithKline) and Bristol Myers-Squibb. Dr. Rossignol has authored more than 100 peer-reviewed publications and holds 31 United States Patents on new drugs. He held faculty positions with the University of Paris and Stanford University in the United States as well as many other adjunct/visiting/clinical positions in the United States, the United Kingdom, Egypt and Peru. He also served as consultant and later expert in parasitic diseases at the World Health Organization between 1980 and 1991.
Mr. Burks has more than 20 years of corporate experience in operations and finance with responsibility for management, debt financings, capital formations and equity transactions including initial public offerings, mergers and acquisitions, corporate formations and restructurings, product diversification evaluations, organization and personnel assessments and corporate governance in a variety of industries including insurance, health care and information technology. Prior to his corporate positions, he was an assurance partner with Coopers & Lybrand for fourteen years. He is a certified public accountant and holds a Bachelor of Science degree in Accounting and Business Administration from Troy University.
Dr. Bréchot is Executive Director of the Romark Institute for Medical Research. He also serves as a professor at the University of South Florida, President of the Global Virus Network and Honorary President of the International Coalition to Eliminate HBV (ICE-HBV). Prior to joining Romark, he was head of the hepatology department at Necker-Enfants Malades Hospital, head of a research unit at INSERM/Paris Descartes University, then President of the French INSERM, Vice-President of the Institut Merieux and finally President of the Pasteur Institute.
Mr. Richiusa has more than 40 years of experience in pharmaceutical manufacturing. He began his career with Ciba-Geigy in Argentina and spent most of his career with Schering-Plough in Argentina, Venezuela, Ecuador and Puerto Rico. Eduardo has also consulted for a number of multinational pharmaceutical companies with respect to pharmaceutical manufacturing operations in Puerto Rico and around the world. Eduardo holds a degree in Pharmacy from the University of Buenos Aires.
Dr. Bardin is Vice President of Medical Affairs. Since joining Romark in 2007, he has worked in Medical Affairs as a Medical Science Liaison and then in Clinical Operations, first as Director of Clinical Research and later as Vice President of Research and Development. Before joining Romark, he was a Pharmacy Coordinator in the BayCare Health System and then Clinical Science Liaison for Axcan Pharma (now part of Allergan). Dr. Bardin is a Board-Certified Pharmacotherapy Specialist, and he holds a Bachelor of Science degree in Chemistry from Florida State University and a Pharm.D. degree from the McWhorter School of Pharmacy at Samford University.
Mr. Pasinski has more than 25 years of experience in pharmaceutical manufacturing and quality systems and presently leads Romark’s Technical Operations department, supporting commercial and clinical manufacturing and new product development. Prior to joining Romark, he worked for Baxter Healthcare. Mr. Pasinski holds a Bachelor of Science degree in Chemistry from Purdue University and a Master of Business Administration degree from DeVry University in Chicago.